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INTRODUCTION 
 
Osteosarcoma is the most common malignant neoplasm of 
bone1 . It occurs most often in bones around knee joint and 
humerus of young people. Due to rapid and aggressive nature of 
the disease, the traditional treatment for osteosarcoma was 
amputation of the affected limb. In the 1970s, two year survival 
rates were fifteen to twenty percent2. However over the past 3 
decades, the prognosis for these patients has changed dramatically. 
The development of chemotherapy agents have revolutionised the 
treatment of osteosarcoma by reducing the mortality. In addition 
the advances in imaging and new materials have provided the 
surgeon broader range of operative alternatives. 
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AIMS AND OBJECTIVES 
 
1. To study long term survival of patients with  extremity 
osteosarcoma  treated by limb salvage surgery 
2.  To identify prognostic factors influencing survival 
3.  To identify risk factors for local recurrence 
4.  To assess functional assessment of patients following limb salvage 
surgery 
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  REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
Osteosarcoma is a primary malignant tumor of bone, 
deriving from primitive bone forming mesenchyme and 
characterised by production of osteoid tissue or immature bone by 
the malignant proliferating spindle cell stroma3. Only  half the bone 
tumors in childhood are malignant, of these osteosarcoma is the 
most frequent, accounting for 35% of all primary sarcomas of 
bonw and 56% of malignant tumors in the first two decades of 
life4.  
The peak incidence of osteosarcoma occurs in second decade 
of life during the adolescent growth spurt, a feature that suggests a 
relationship between rapid bone growth and the development of 
osteosarcoma. Evidences to support this relationship are as follows. 
First, patients with osteosarcoma are taller than their age peers. 
Second, these tumors occur at an earlier age in girls than boys, 
corresponding to the more advanced skeletal age and earlier 
adolescent growth spurt of girls. Third osteosarcoma has a 
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predilection for the metaphyseal portions of the most rapidly 
growing bones in adolescents – the distal femur, proximal tibia and 
proximal humerus. This has lead to the speculation thatbone 
tumors arise from an aberration of the normal process of bone 
growth in length and remodelling5.  
ETIOLOGY 
The etiology of osteosarcoma is unknown. A viral etiology 
was suggested based on evidence that bone sarcomas can be 
induced in select animals by viruses6  or cell free extracts of human 
osteosarcoma7.   
The only environmental agent known to produce bone 
sarcomas in humans is ionizing radiation. Radiation is implicated 
in 3% of osteosarcomas8. The latent period between radiation 
exposure and development of osteosarcoma ranges from 4 to more 
than 40 years (median 12 to 16 years). Osteosarcoma has been 
reported in patients with paget disease and cases of osteosarcoma 
after the age of 40 years are almost exclusively associated with this 
premalignant condition3. Approximately 2% of patients with paget 
disease develop osteosarcoma. Histologically, osteosarcomas in 
patients with paget disease are similar to conventional 
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osteosarcoma, although multiple bone involvement is frequent and 
the prognosis is poor. 
Other benign bone lesions are also associated with an 
increased risk of the development of osteosarcoma. Lesions 
predisposed to such malignant degeneration are solitary or multiple 
osteochondroma, solitary enchondroma or enchondromatosis 
(Oliers disease), multiple hereditary exostoses, fibrous dysplasia, 
chronic osteomyelitis, sites of bone infarcts and sites of metallic 
implants for benign conditions. Genetic syndromes associated with 
osteosarcoma are Rothmund-Thomson syndrome (RTS)- 
characterised by autosomal recessive pattern, characteristic skin 
rash (poikiloderma), small stature and skeletal dysplasias; 
Hereditary retinoblastoma and Li Fraumeni syndrome. 
PATHOLOGY 
The diagnosis of osteosarcoma is based on histopathologic 
criteria in correlation with radiologic appearance. The histologic 
diagnosis of osteosarcoma depends on the presence of a frankly 
malignant sarcomatous  stroma associated with production of 
tumor osteoid. Because osteosarcomas are thought to arise from  a 
stem mesenchymal cell capable of differentiating toward fibrous 
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tissue, cartilage or bone; osteosarcoma shares many features with 
chondrosarcoma and fibrosarcoma. However chondrosarcoma and 
fibrosarcoma are distinguished from osteosarcoma by their lack of 
production of osteoid, the sine qua non for the diagnosis of 
osteosarcoma. 
Osteosarcomas are classified depending on the histological 
type or the location within bone as central or surface osteosarcoma 
and whether primary or secondary osteosarcoma. The WHO 
classification of osteosarcoma is as follows, 
1. Classic or Conventional osteosarcoma 
a. Osteoblastic osteosarcoma 
b. Chondroblastic osteosarcoma 
c. Fibroblastic osteosarcoma 
2. Telangiectatic osteosarcoma 
3. Small cell osteosarcoma 
4. Low grade central osteosarcoma 
5. Parosteal osteosarcoma 
6. Periosteal osteosarcoma 
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7. High grade surface osteosarcoma 
8. Secondary osteosarcoma 
CLINICAL PRESENTATION, NATURAL HISTORY AND 
PATTERN OF SPREAD 
The majority of patients with osteosarcoma present with pain 
over the involved bone, with or without a mass. The average 
duration of symptoms is 3 months, although a history of 6 months 
or longer is not uncommon. Parosteal osteosarcomas in particular 
can be associated with painful symptoms of several years duration, 
reflecting the indolent behaviour of this tumor.  
Approximately 15% to 20% of patients with osteosarcoma 
present with visible macrometastatic disease9. Majority of these 
metastases are found in lungs, although a small minority of patients 
present with bone metastases who carry an extremely grave 
prognosis. Involvement of lymph nodes is unusual but a poor 
prognostic sign.  
BIOLOGY OF TUMOR GROWTH 
Sarcomas form a solid lesion that grow centrifugally. In a 
benign lesion true capsule surrounds the tumor, which is composed 
8 
 
of compressed normal cells. In contrast the malignant tumor is 
enclosed by a pseudocapsule, consisting of compressed tumor 
cells. This is surrounded by a fibrovascular zone of reactive tissue 
with inflammatory component. The tumor cells extend through the 
pseudocapsule as pseudopods and can detach from the tumor and 
form satellite lesions in the reactive zone, the thickness of which 
varies with the degree of malignancy. 
Skip metastases is a tumor nodule that is located within the 
same bone having the tumor but not in continuity with it. These 
develop by embolization of tumor cells within the marrow 
sinusoids. 
EVALUATION  
PLAIN RADIOGRAPH 
Plain radiography is the first imaging modality when the 
patient presents with bone symptoms. Considering the age and the 
tumor characteristics depending on site, sclerotic/ lytic, margins, 
periosteal reaction, morphologic appearance and the matrix, a 
clinic-radiologic diagnosis of malignant bone tumor can be done. 
Chest x-ray is done as a part of staging workup. 
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CT/MRI OF LOCAL PART 
CT and MRI are both complementary in the evaluation of 
bone sarcomas. Intraosseous  and extraosseous extension are 
depicted with certainty by CT. Soft tissue extension and marrow 
extension, apart from skip lesions are well demonstrated by MRI.  
BONE SCAN 
Bone scan is done for estimating the exact tumor extension, 
and ruling out bony metastasis and polyostotic involvement. 
During limb salvage procedures, removal of bone 4cms from 
scintigraphic abnormality is considered as safe margin.  
CT CHEST 
Spiral CT chest is done to rule out lung metastasis which can 
occur in 10% of patients at presentation. Lung metastasis at 
presentation does not preclude limb salvage, when the primary 
tumor is suitable for salvage surgery, as discussed below. 
POSITRON EMISSION TOMOGRAPHY 
(18f) Fluorodeoxy-D-glucose PET for bony and pulmonary 
evaluation is in its evolutionary phase and preliminary reports are 
available for staging, diagnosis, staging, assessment of response 
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and follow-up. FDG-PET is still investigational and early studies 
have shown that PET imaging is not accurate in determination of 
pulmonary metastasis in osteosarcoma. 
All these imaging can be repeated following preoperative 
chemotherapy to assess the tumor response. 
STAGING 
The musculoskeletal tumor society (MSTS) formulated a 
surgical staging system for bone sarcomas. This staging system 
described by Enneking et al is based on GTM: grade (G), location 
(T) and lymph node involvement and metastases (M)10.  The grade 
G is further divided into G1, low grade and G2, high grade. T 
denoting the site of lesion may be intra-compartmental (T1) or 
extra-compartmental (T2). 
The surgical system developed by Enneking et al is as 
follows: 
Stage IA (G1 T1 M0): Low-grade intracompartmental lesion,  
  without metastasis 
Stage IB (G1 T2 M0): Low-grade exrracompartmental lesion,  
  without metastasis 
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Stage IIA (G2 T1 M0): High grade intracompartmental lesion,  
  without metastasis 
Stage IIB (G2 T2 M0): High grade extracompartmental lesion,  
  without metastasis 
Stage IIIA (G1 or G2 T1 M1): Any grade intracompartmental  
  lesion, with regional nodal or distant metastasis 
Stage IIIB (G1 or G2 T2 M1): Any grade extra compartmental  
  lesion, with metastasis 
AJCC AND UICC BONE TUMOR CLASSIFICATION 
In 1983, the American Joint Committee on Cancer 
recommended a staging system for the malignant tumors of bone. 
This system has undergone several modifications and is now in its 
sixth edition(2002)11. A two tired grading system is used in TNM. 
  Primary tumor (T) 
  Tx Primary cannot be assessed 
  T0 No evidence of primary tumor 
  T1 Tumor 8cm or less in greatest dimension 
  T2 Tumor more than 8cm in greatest dimension 
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  T3 Discontinuous tumors in the primary bone site 
  Regional lymph nodes (N) 
  Nx Regional lymph nodes cannot be assessed 
  N0 No regional lymph node metastasis 
  N1 Regional lymph node metastasis 
  Distant metastasis (M) 
  Mx Distant metastasis cannot be assessed 
  M1 No distant metastasis 
  M1a Lung  
  M1b Other distant sites 
  Histological Grade (G) 
  Gx Grade cannot be assessed 
  G1 Well differentiated – Low grade 
  G2 Moderately differentiated – Low grade 
  G3 Poorly differentiated – High grade 
  G4 Undifferentiated – High grade 
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STAGE GROUPING 
IA   T1   N0   M0  G1,2  Low grade 
IB   T2   N0   M0  G1,2  Low grade 
IIA   T1   N0   M0  G3,4  High grade 
IIB   T2   N0   M0  G3,4  High grade 
III   T3   N0   M0  Any G 
IVA   Any T  N0   M1a  Any G 
IVB   Any T  N1   AnyM Any G 
Any T  Any N  M1b  Any G 
  
TREATMENT 
 
  SURGICAL MANAGEMENT OF PRIMARY 
Osteosarcomas had traditionally been treated by 
amputations. Recent advances in molecular medicine, the 
construction of better and longer lasting prosthesis and 
biomaterials and the use of chemotherapy have had a definitive 
impact on the prognosis and therapeutic approach for 
osteosarcoma. Nowadays ablative surgery (amputations and 
disarticulations) are reserved for tumors with significant 
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neurovascular involvement and poor distal extremity function. 
Additional indications for amputation include soft tissue 
contamination due to pathologic fracture or a poorly performed 
biopsy site. Following initial treatment, failed attempts at limb 
salvage and/or persistent local recurrence are again treated by 
amputation.  
LIMB SALVAGE SURGERY 
Campanacci and Laus proposed predetermined levels of 
amputation for the common presentations of osteosarcoma, 
emphasizing the danger of conservative surgical margins12. Even 
with this radical surgical approach, the mortality of patients before 
the advent of chemotherapy and more advanced imaging and 
surgical techniques was close to 80% at 5 years 
Simon et al published the first evidence-based study 
supporting the benefits of limb-salvaging procedures for the 
treatment of bone tumors13. Their multicenter study, which 
included 227 patients with osteosarcoma of the distal end of the 
femur, reported the rates of local recurrence, metastasis, and 
survival. Three groups of patients where studied: patients in group 
1 had a limb-sparing procedure, patients in group 2 had an 
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AKA,and in group 3,a hip disarticulation was the procedure of 
choice. The Kaplan-Meier curves of the patients who survived and 
the percentage of patients without recurrent disease showed no 
statistical difference among the three surgical groups after a mean 
length of follow-up of 5.5 years (Mantel-Cox test: P=.8). Limb-
salvage surgery was as safe as an amputation in the management of 
patients with high-grade osteosarcoma.  
Limb-salvage procedures can be divided into 
1. Arthrodesis   
2. Allograft  
a. Osteoarticular allograft 
b. Intercalary allogaft 
3. Metallic prosthesis 
a. Modular prosthesis 
b. Custom-made mega prosthesis 
c. Expandable prosthesis 
4. Allograft-Prosthetic composites 
5. Rotation plasty 
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 ARTHRODESIS 
An arthrodesis is usually obtained using bone allografts, 
vascularized autografts, or both. An arthrodesis provides a stable, 
durable reconstruction, resistant to physical stress and activity and 
requiring limited postoperative follow-up. In addition, once the 
allograft heals, patients seldom require additional surgical 
procedures.  
The disadvantages include the loss of knee extension with 
alterations in gait and function such as rising from a chair, 
squatting  and social sitting (bus,train), an increased energy 
expenditure, and the additional abnormal mechanical stress to the 
hip and spine. With the advent of metallic prosthesis arthrodesis is 
seldom performed nowadays. 
  OSTEOARTICULAR ALLOGRAFTS 
Osteoarticular allografts are one alternative for 
reconstruction for tumor defects of the proximal tibia, distal femur 
and proximal humerus. Grafts are procured according to specific 
guidelines and stored in a fresh frozen state at -800C until needed. 
They are size matched to the specific patient using radiographs of 
the involved bone and allograft. Allografts are immunogenic but 
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the immune response is reduced by the fact that they are 
nonvascularized and freezing reduces the antigenicity. The 
allograft is not resorbed but host invasion occurs primarily at the 
allograft-host junction and along the surface of the bone.  
Osteoarticular allografts have certain advantages compared 
with metallic prosthesis. They provide articular surface for the 
adjacent bone, obviating the need to resect the articular surface and 
the growth plate. Allograft provides ligaments for joint 
reconstruction including cruciate ligaments and sites for host 
tendons. Once the osteosynthesis heals, it is anticipated that the 
longevity of the allograft is superior to metallic prosthesis because 
they are not subjected to loosening, particulate wear debris and 
mechanical breakage. 
Allografts have obvious potential problems and are subject 
to fracture, non-union, joint instability and higher infection rate. 
The procedure is technically challenging and has a prolonged 
rehabilitation period. 
  INTERCALARY ALLOGRAFTS 
When osteosarcomas are located in the diaphysis, the 
adjacent joints and metaphyses can be spared. In young patients 
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where a margin of bone can be obtained  while preserving the 
proximal and distal metaphysis, an intercalary allograt can be 
employed to reconstruct the diaphysis. Fixation can be achieved 
with plates so that the growth plates can be spared; or if the 
epiphysis is needed for fixation, the fixation devices (screws) in the 
epiphysis can be removed to allow growth once the osteosynthesis 
has healed.  
  METALLIC PROSTHESIS 
  Endoprosthetic reconstruction is performed with the 
use of modular oncology prosthesis or custom made prosthesis. 
The modularity gives the surgeon the opportunity to restore the 
length of the limb in the operating room, matching the amount of 
bone resected. Osteosarcomas are dynamic tumors that change with 
time and treatment. The metallic prosthesis can be fixed to the 
bone with polymethylmethacrylate or a press-fit porous stem can 
be used instead. The joint bearing is a rotating hinge that has some 
freedom of movement, but it will always be more constrained than 
a normal knee. The disadvantages include loosening, excessive 
wear, material failure, and stiffness. 
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 The custom made prosthesis is customized to individual 
patient. These prosthesis are cheaper when compared to the 
modular ones, and are made up of the same biomaterials. With the 
concept of neo-adjuvant chemotherapy the delay in manufacturing 
the prosthesis does not have any significant impact on the survival. 
Prosthesis failure occur due to loosening at the prosthesis-bone 
interface, infection and fracture. Infections are significant risk 
factor for endoprosthesis with rates ranging from 0% to 35%. 
EXPANDABLE PROSTHESIS 
A relatively novel technique of limb salvaging, especially in 
skeletally immature patients, is the use of an expandable prosthesis 
for patients with osteosarcoma  The location of these tumors in the 
growing areas of bone commonly mandates the removal of the 
affected growth plate. Subsequent continued growth in the 
contralateral extremity results in limb-length inequality. The distal 
femoral growth plate produces 1.6 cm in longitudinal growth per 
year. From a functional standpoint, the lower extremities should be 
of equal length if possible. If left untreated, limb-length 
discrepancies can result in low back pain and even compensatory 
scoliosis. Gait disturbances are also commonly observed. 
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Custom expandable prostheses have been in use worldwide 
since 1976 and in the United States since 1983. The system 
consists of a fixed stem with a screw or a multiple plate extension 
mechanism . In all of the commonly used expanding mechanisms,a 
surgical procedure is required for the subsequent expansions. 
The Phenix Growing Prosthesis (Phenix Medical, Paris, 
France) was designed in the early 1980s. Although this prosthesis 
is not frequently used at the present time, it helped spark the 
interest in the current models of expandable prostheses. 
The Stanmore expandable prosthesis (Stanmore Implants, 
Stanmore Middlesex, United Kingdom) has been recently 
introduced to the United States with a limited Food and Drug 
Administration approval. When the implanted prosthesis is placed 
at the centre of a rotating electromagnetic field, the poles of a 
magnet within the implant are captured,causing it to rotate in 
synchrony. The external field rotates at a fixed speed, causing the 
implant to expand at a rate of 0.23 mm per minute (1 mm every 4 
minutes). Current indication for the procedure is children who are 
expected to develop a limb-length discrepancy greater than 4 cm 
after the resection of an osteosarcoma.  
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  ALLOGRAFT-PROSTHETIC COMPOSITES 
Another alternative to limb reconstruction is to combine a 
standard knee or proximal humerus prosthesis with an allograft for 
lesions about the knee or shoulder. This offers the advantage of 
joint reconstruction employing a more standard arthroplasty and 
restoring bone stock with allograft bone. The prosthesis allows 
joint stability and the allograft provides attachment for tendons. At 
all sites the composites allow for modularity and in theory may 
provide a more durable reconstruction than osteoarticular allografts 
or metallic prosthesis. 
  ROTATIONPLASTY 
Young children with high grade sarcomas of the knee have 
limited options for reconstruction following resection of the 
sarcoma. Limb sparing procedures have the drawbacks of activity 
restrictions, high complication rate, limb length inequality and 
complexity. An above knee amputation for a distal femoral 
osteosarcoma in a very young patient leaves the child with a very 
short lever arm to power a prosthesis and becomes shorter as the 
child grows. 
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The operation described by Borggeve and adopted for 
congenital defects by Van Nes has been applied to the tumor 
setting by Salzer. The reconstruction employs the distal leg to be 
rotated 160 to 180 degrees and this provides the advantage of a 
longer lever arm and an active “knee” joint provided by the ankle 
and foot. 
The indications for rotationplasty include a distal femoral or 
a proximal tibial osteosarcoma in a skeletally immature patient or a 
salvage procedure for a failed distal femoral reconstruction. The 
advantages are the wide margin which includes the skin, adjacent 
knee joint and thigh muscles, the avoidance of phantom limb pain, 
rapid healing of the osteosynthesis site and a relatively low 
complication rate. 
The obvious drawback is the appearance which is repulsive 
at some times. Interestingly the young child does not view the 
procedure as an amputation because the foot remains and with a 
good prosthesis he is able to function better than other amputees. 
Studies have not shown any adverse psychological outcomes. 
Recently the number of patients willing to undergo this procedure 
has diminished, many prefer to try a limb sparing procedure and 
reserve rotationplasty until or unless it fails. 
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  CHEMOTHERAPY IN MANAGEMENT OF OSTEOSARCOMA 
 Although control of the primary tumor is reliably 
accomplished by surgery, data from historical studies indicate that 
more than 80% of patients treated only with surgery will develop 
metastatic disease. Microscopic subclinical metastasis is present at 
the time of diagnosis. Before 1970, none of the drugs tested 
produced responses in more than 15% of the patients. More 
promising results were observed in the 1970s and 1980s, in trials of 
doxorubicin, high-dose methotrexate, cisplatin and ifosfamide. 
PREOPERATIVE CHEMOTHERAPY 
The administration of neoadjuvant chemotherapy initially 
evolved from early attempts at limb salvage surgery at the 
Memorial Sloan-Kettering Cancer Centre where customized 
endoprosthesis were used for limb reconstruction. Because 
fabrication of these devices required 2 to 3 months, patients were 
treated with chemotherapy after biopsy while awaiting surgery41. 
The only randomized trial by Pediatric Oncology Group 
(POG) failed to show survival benefit for patients receiving 
preoperative chemotherapy when compared to patients undergoing 
immediate surgery14. There is no other randomized or 
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nonrandomized studies comparing neoadjuvant chemotherapy vs 
immediate surgery and adjuvant chemotherapy in osteosarcoma 
patients. Preoperative chemotherapy has become the standard 
owing to the fact that tumor response to chemotherapy can be 
predicted and has been consistently shown to be an important 
predictor of survival.  Although several grading systems exist for 
assessing the histological response to preoperative chemotherapy, 
the general consensus is more than 90% necrosis is considered 
good response and these patients fair better in survival. 
METASTASIS AT PRESENTATION 
The presence of metastatic disease at presentation continues 
to be a poor prognostic factor, with most studies showing survival 
rates in the range of 20%. Limb salvage surgery could still be 
considered if an aggressive approach could be followed with 
resection of disease at all sites and chemotherapy. In a large 
analysis of COSS database that included more than 1700 patients, 
the 10-year survival probability was 40% for patients who were 
able to have all metastatic disease resected9. 
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PATHOLOGICAL FRACTURE 
Pathological fracture was traditionally treated by amputation. 
With  advent of effective chemotherapy and better techniques of 
limb salvage surgery, pathological fracture through an 
osteosarcoma is no more considered a contraindication for limb 
salvage. Earlier study by Steadman et al who reported on nine limb 
salvage and eight amputations in patients with osteosarcoma 
induced pathologic fracture, have shown one local recurrence in 
limb salvage group but no difference in survival between the two 
groups15. Recent study from Lee Moffitt Cancer Institute, by Abeid 
and Abdelmegid, have evaluated on 31 bone tumor patients with 
pathological fracture of which 17 were osteosarcoma16. The local 
recurrence rate reported was 6%.  
SOFT TISSUE EXTENSION 
Contraindications to limb salvage surgery are major 
neurovascular involvement, inappropriate biopsy site, infection, 
immature skeletal age and extensive muscle involvement17. 
Extensive muscle involvement is considered when enbloc resection 
entails removal of entire tumor with surrounding normal tissue and 
26 
 
when enough muscle is not available to reconstruct a functional 
extremity18. 
Functional assessment is done following limb salvage 
surgery in bone and soft tissue tumors are done using either 
Musculoskeletal tumor society scoring system (MSTS) or the 
Toronto extremity salvage score (TESS). In the modified MSTS 
score proposed by Enneking et al19 six factors- pain, function, 
emotional acceptance, supports, walking ability and gait are 
analyzed. Functional assessment following limb salvage surgery 
has been compared with amputation. Several  studies  have shown 
limb salvage surgery is associated with better functional outcome 
than that observed with amputation but psychological outcome for 
patients undergoing limb salvage surgery is not clearly superior to 
that of amputees. 
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MATERIALS AND METHODS 
 
Three hundred and forty seven osteosarcoma patients were 
treated at the institute between 1990 and 2005. Of these 105 
patients were treated by limb salvage surgery. Five patient’s case 
records could not be retrieved and entire details of treatment were 
not available in another eight case records. Finally ninety two 
patients were analyzed. The case records of these patients were 
reviewed, follow up was updated by active and passive means.  
DIAGNOSTIC METHODS 
All patients suspected of bone sarcoma were evaluated with 
local part x-ray, CT or MRI of the affected limb. Chest x-ray, CT 
chest and Tc99m bone scintigraphy was done as part of metastatic 
workup. ‘Jamshidi’ needle biopsy was done for definitive 
diagnosis. For patients who had biopsy done elsewhere, the slides 
or paraffin blocks were reviewed. 
CHEMOTHERAPY 
Different chemotherapy protocols have been used in the 
sixteen year study period. In the initial years till 1999-2000, 
cyclophosphamide, adriamycin and cis-platin were used. In the 
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subsequent years ifosphamide, adriamycin and cis-platin were 
used. Three to four cycles of neo-adjuvant chemotherapy was 
given followed by limb salvage surgery and the remaining cycles 
of chemotherapy to a total dose of six.  In 2003 and 2004,pre-
operative intra-arterial chemotherapy was given as a part of a 
project. (Ratan Tata Project for borderline tumors for limb salvage) 
SURGERY 
Clinical assessment of response was done after each pre-
operative cycles. After a minimum of three cycles, imaging for 
reassessment is done only for borderline tumors for limb salvage. 
The number of neo-adjuvant chemotherapy cycles were determined 
by the time taken for customizing prosthesis. All patients of limb 
salvage surgery underwent custom made mega prosthesis. 
Histopathological analysis included percentage of necrosis, and 
were analyzed as those above 90% necrosis and below 90% 
necrosis. 
 
FOLLOW UP 
All patients were followed up according to institution 
protocol; monthly in first year, two monthly in second year, 3 
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monthly in third year, semi-annually in fourth and fifth years and 
then annually. Clinical examination and chest x-ray is done at each 
visit. Further investigations were done as symptoms warranted.  
MANAGEMENT OF COMPLICATIONS 
Prosthesis complications were managed appropriately. Redo 
prosthesis was attempted in cases of fracture prosthesis, prosthesis 
removal was reserved for cases where prosthesis could not be 
replaced.  Prosthesis infection were managed with removal of 
prosthesis or amputation.  Amputation was done for patients who 
developed local recurrence. Patients who had lung metastases 
feasible for resection underwent lung metastatectomy. 
FUNCTIONAL OUTCOME 
Functional assessment was done using musculoskeletal 
tumor society scoring system19. Assessment was done by personal 
interview, postal survey and telephone interview. 
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Scoring system of the international society of limb salvage 
   
Score 
Points 
Pain Function Emotional 
acceptance 
Supports Walking 
ability 
Gait 
5 None No 
restrictions 
Enthuse None Unlimited Normal 
4 Intermediate  Intermediate Intermediate Intermediate Intermediate Intermediate 
3 Modest Restriction 
in 
recreational 
activities 
Satisfied Brace Limited Minor 
cosmetic 
2 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate 
1 Moderate Partial 
disability 
Accepts One cane or 
crutch 
Household Major 
cosmetic, 
minor 
handicap 
0 Severe Total 
disability 
Dislikes Two canes 
or crutches 
Unable to 
walk 
unaided 
Major 
cosmetic, 
major 
handicap 
 
STATISTICAL ANALYSIS 
Statistical analysis was done by actuarial method, calculated 
using SPSS 10.0 (SPSS software Inc USA). Prognostic factors for 
survival and local recurrence were analyzed by Cox proportional 
hazards regression model. 
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RESULTS 
 
Of the total 92 patients, 62 were male and 30 were female 
(2.1:1). The mean age of presentation  was 19 years . Mean follow 
up period was 57 months, range 3 months to 156 months. 
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Osteosarcoma was located in lower extremity in 84 patients 
and upper extremity in 8 patients. Most common sites were distal 
femur in 56.5% and proximal tibia in 33%. 
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Osteosarcoma was diagnosed in 41 patients by ‘Jamshidi’ 
needle biopsy. Remaining 51 patients were diagnosed by open 
biopsy. Only 6.5% (n=6), of patients had a needle biopsy outside 
whereas 38% (n=36) of patients at this institute underwent needle 
biopsy. In contrast 41.3% (n=38) had an open biopsy done outside, 
compared to 14% (n=13)  in the institute, in the same time period. 
Osteosarcoma can very well be diagnosed by needle biopsy, 
precluding the need for open biopsy.  
Limb salvage surgery was done using custom made mega 
prosthesis. Post-operative morbidity is as follows. 
Morbidity  Number of 
patients 
Marginal necrosis, no intervention 4 
Marginal necrosis, secondary suturing 5 
Marginal necrosis, excision & SSG 2 
Marginal necrosis, excision & flap reconstruction 2 
Foot drop 7 
Ischemia leading to amputation  1 
Infection resulting in amputation (within 30 days) 1 
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Seven patients (7.6%) had foot drop, of which two was in 
distal femoral tumor resection and rest were in proximal tibial 
tumor resection. Foot drop were temporary and resolved in four to 
six months.  
Five year overall survival was 67.1% and  disease free 
survival was 57.5%. 
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All but five patients received neo-adjuvant chemotherapy. 33 
patients (39%) achieved > 90% necrosis (Good responders). 54 
patients (62%) achieved < 90% necrosis (Poor responders). 
Survival significantly differed in both. Five year overall survival 
for good responders was 88% and for poor responders was 59% 
Following factors were analyzed by Cox regression analysis 
for survival and local recurrence. 
1.Age group: < 20 vs > 20 
2.Number of preoperative chemotherapy cycles: < 3 vs >3 
3.Size of the primary tumor: < 8cm vs > 8cm 
4.Percentage of necrosis: > 90% vs < 90% 
5.Biopsy: Needle biopsy vs Open biopsy 
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Prognostic factors analyzed for survival 
                             Univariate analysis                                   Multivariate analysis 
Variables Stratification Number Hazard 
ratio 
P Hazard 
ratio 
P 
Age group <20  
 > 20  
65 
27 
HR 0.91 
(0.38-
2.16)  
NS HR0.68       
(0.23-
1.96)  
NS 
No: of 
chemo 
< 3 
 > 3  
65 
27 
HR1.78 
(0.81-
3.87)  
NS HR 2.03      
(0.84-
4.94)  
NS 
Size < 8cm 
 >8cm  
23 
69 
HR1.46 
(0.58-
3.68)  
NS HR 1.02      
(0.39-
2.67)  
NS 
Necrosis > 90% 
 <90%  
52 
33 
HR0.07 
(0.01-
0.51)  
<0.005 HR 0.07      
(0.01-
0.51)  
<0.005 
Biopsy  Needle 
 Open  
41 
51 
HR1.36  
(0.63 -
2.94)  
NS HR 1.07      
(0.46-
2.47)  
NS 
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Prognostic factors analyzed for local recurrence 
Unvariate analysis             Multivariate analysis 
Variables Stratification Number Hazard 
ratio 
P Hazard 
ratio 
P 
Age group <20  
 > 20  
65 
27 
HR 1.28 
(0.46-
2.64)  
NS HR1.05     
(0.33-
2.34)  
NS 
No: of 
chemo 
< 3 
 > 3  
65 
27 
HR1.2 
(0.97-
3.66)  
NS HR 2.27    
(1.09-
4.74)  
NS 
Size < 8cm 
 >8cm  
23 
69 
HR1.90 
(0.79-
4.57)  
NS HR 1.68    
(0.66-
4.28)  
NS 
Necrosis > 90% 
 <90%  
52 
33 
HR0.09 
(0.02-
0.37)  
=0.001 HR 0.09    
(0.02-
0.36)  
=0.001 
Biopsy  Needle 
 Open  
41 
51 
HR1.06  
(0.55 -
2.03)  
NS HR 0.97    
(0.48-
1.96)  
NS 
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Of all the factors analyzed, only response to chemotherapy 
was found to be a significant risk factor for both local recurrence 
and survival. 
Twelve (13%) patients developed local recurrence. 75% of 
the local recurrences occured in the first year following surgery 
and 92% occurred within twenty-four months. Of these twelve 
patients, five developed distant (lung) metastases. Eight patients 
were treated by amputation. Remaining four were adviced 
supportive care in view of associated systemic metastasis. At the 
time of analysis, among these twelve patients, four are alive 
without disease, six expired and two lost to follow up. 
Of these twelve patients one had pathological margin 
positive. 8 underwent open biopsy for tissue diagnosis. But in the 
final histopathology following neo-adjuvant chemotherapy none of 
them had tumor in biopsy scar. Majority of patients (51 patients) in 
this study underwent open biopsy for diagnosis. This factor was 
analyzed compared with needle biopsy as a risk factor for local 
recurrence. Though local recurrence is more in patients undergoing 
open biopsy, this was not statistically significant. 
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  TYPE OF BIOPSY IN RELATION TO LOCAL RECURRENCE 
 
 
 
 
 
 
 
Four patients had pathological fracture at presentation who 
received neoadjuvant chemotherapy followed by limb salvage 
surgery. None of these patients developed local recurrence. 
In these 92 patients who underwent limb salvage surgery, a 
subgroup of patients were considered to have extensive soft tissue 
disease based on the following criterias – if more than one 
compartmental muscle is involved radiologically, discontinuous 
lesion is found intra-operatively or in the pathological examination 
of the specimen, or if the tumor infiltrates the surrounding muscle 
and extends to superficial fascia. 
 Local 
recurrence 
No local 
recurrence 
Total 
Jamshidi needle 
biopsy 
4 (9.8%) 37 41 
 
Open biopsy 8 (15.7%) 43 51 
p=0.401 
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Based on these criterias, 7 patients had tumor confined to 
bone, 71 patients had tumor with minimal soft tissue extension and 
14 patients had extensive soft tissue extension. In the group with 
bone only disease none of the patient developed local recurrence. 
In patients who had minimal soft tissue, 9 patients (12.7%) 
developed local recurrence and 16 patients (22.5%) developed 
distant metastasis. On the contrary approximately double the local 
recurrence and distant metastasis were found in the group with 
extensive soft tissue involvement- 3 patients (21.4%) developed 
local recurrence and 7 patients (50%) developed distant metastasis. 
The 5 year overall and disease free survival is as follows. 
 
 
 
 
 
 
 
Groups  Overall survival Disease free 
survival 
Confined to bone 85.7% 84.6% 
Minimal soft tissue extension 72.3% 61.7% 
Extensive soft tissue extension 49.3% 30.7% 
p=0.37 p=0.33 
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   Local recurrence in these groups is as follows. 
 
 
 
  
 
 
 
 
 
The overall survival in patients who had amputation for 
osteosarcoma in our institute is 43.1% and disease free survival is 
35.5%, in the same period. Patients who had extensive soft tissue 
disease and underwent limb salvage had survival comparable to 
patients who underwent amputation. 
Twenty one (23%) patients developed distant metastasis. 
Lungs were the predominant site of metastasis.  Lungs were the 
predominant site of metastasis (19 patients), two had soft tissue 
Groups  Local 
recurrence 
No local 
recurrence 
Total  
Confined to bone 0 7 7 
Minimal soft tissue 
extension 
9 (12.7%) 62 71 
Extensive soft tissue 
extension 
3 (22.5%) 11 14 
 p=0.382 
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metastasis, one had bone and one had both lung and bone 
metastasis. Metastatectomy was done in two patients. At the end of 
our study, of these twenty one patients, one patient is alive and 
disease free, one is alive with disease and nineteen expired 
Prosthesis survival rate is 57% Prosthesis infection occurred 
in 11 patients(11.9%). Prosthesis fracture occurred in 17 
patients(18.4%). Both were common in distal femoral prosthesis. 
 
Prosthesis related morbidity Number of 
patients 
Infection (After 30 days) 11 (11.9%) 
Fracture  17 (18.4%) 
Displacement 2 
Loosening of screws 1 
Remnant bone fracture 2 
 
Thirty revisions were done for these 92 patients. Apart from 
infection and fracture, the number of revisions and amputations 
were also high in distal femoral prosthesis reconstruction. 
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Site of 
tumor 
Number of 
patients 
Number 
of 
infection 
Number 
of 
fractures 
Number 
of 
revision 
Number of 
amputations 
Number of 
local 
recurrence 
Distal 
femur 
52 8 14 19 13 7 
Proximal 
tibia 
31 2 3 9 3 2 
Proximal 
humerus 
6 1 - 1 2 2 
Proximal 
femur 
1 - - - - - 
Radius 1 - - - - - 
Ulna 1 - - 1 1 1 
Total 92 11 17 30 19 12 
Of the total of 92 patients, forty are surviving with 
prosthesis. Functional assessment was done using modified 
Musculoskeletal tumor society score  (MSTS) score. The average 
MSTS score was 25 out of 30 (86%), revealing a good functional 
outcome. 
44 
 
DISCUSSION 
 
Osteosarcoma is the most common primary bone 
malignancy in children with an overall incidence of approximately 
one per 100,000 per year16. Osteosarcoma typically presents 
between five and thirty years of age20. The predominant age at 
presentation in our study is in second decade of life. As reported in 
most series22, males were twice commonly affected than females in 
our study. 
Osteosarcomas can affect any bone but predominantly 
involves the metaphysis of long bones in appendicular skeleton 
(eighty percent)21. The most common sites affected are distal 
femur, proximal tibia and proximal humerus. Over half of 
osteosarcomas occur from the knee area21. Similarly majority of 
limb salvage surgery is feasible in tumors around knee joint. In our 
study limb salvage surgery was done in 89% of tumors in knee 
area. (Distal femur 52, proximal tibia 31, proximal humerus 6, 
proximal femur 1, radius 1, ulna 1) 
The most common presentation had been pain and swelling. 
Initial work-up was x-ray of local part and chest. Further 
evaluation was by CT or MRI or both of the affected bone and 
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adjacent joint depending on individual case. CT of chest is done if 
x-ray chest is normal. Bone scan is done as part of local imaging 
and to rule out bone metastases. Prosthesis measurement is done 
based on bone scan extent of tumor size and scannogram of the 
affected limb.  Patients found to be suitable for limb salvage and 
non-metastatic, are planned for limb salvage surgery. 
Osteosarcoma was diagnosed in 41 patients by ‘Jamshidi’ 
needle biopsy. Remaining 51 patients were diagnosed by open 
biopsy, of which 38(74.5%) were done elsewhere before referring 
to our institute.  Only six of forty one needle biopsies were done 
outside. Osteosarcoma can very well be diagnosed on needle 
biopsy and better be done by the surgeon / centre specialized in 
limb salvage surgery. The principle of biopsy cannot be 
overemphasized because a poorly executed  biopsy can preclude 
limb salvage surgery23. In a report from M.D.Anderson cancer 
centre only 19% of patients referred to that institute had a properly 
placed biopsy and 92% of biopsies performed in the same period at 
that centre was needle biopsy24. 
All but five patients received neo-adjuvant chemotherapy. 
Two patients were diagnosed as parosteal osteosarcoma and two as 
low grade osteosarcoma ( One patient had a preoperative biopsy 
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diagnosis of Giant cell tumor of bone). One patient was diagnosed 
as chondrosarcoma on biopsy, but following limb salvage surgery 
found to have chondroblastic variant of osteosarcoma and hence 
received adjuvant chemotherapy. 
The global trend in the management of osteosarcoma is limb 
salvage surgery. The goal of any malignant tumor operation is to 
perform a complete en bloc removal of the tumor with adequate 
margins. The use of neoadjuvant chemotherapy with advances in 
imaging technique have enabled the oncologic surgeon to obtain 
local control rates equivalent to amputation using limb salvage 
surgery25.  
The survival rate of osteosarcoma patients had dramatically 
increased from a meagre fifteen to twenty percent in the 1970s to 
as high as seventy to eighty percent. The survival rates reported in 
recent studies compared to our study is as follows. 
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Journal Author No:of 
patients 
Follow 
up 
years 
EFS 
% 
OS 
% 
J Clin Oncol 
2000;18:4016-
4027 
Bacci et 
al26 
133 10 59 70 
J Clin Oncol 
2002;20:776-
790 
Bielack SS 
et al9 
1702 10 48.9 59.8 
The 
Oncologist 
2004;9:422-
441  
Marina et 
al2 
Rev 
article 
5 
10 
 74 
71 
Our study  92 13 57.5 67.1 
 
The most extensive study is from the German-Austria-
Switzerland study group, in their series of 1702 patients, the ten 
year overall survival rate is 59.8% and the disease free survival rate 
is 48.9%9. In our study the five year overall survival rate is 67.1% 
and the disease free survival rate is 57.5%, which is in comparison 
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with other international studies such as from Rizzoli Institute26 and 
MSKCC2. 
Although there is no survival benefit, preoperative 
chemotherapy has become the standard practice at most centres, 
due to the important survival implications of biologic response to 
such therapy. Although different grading systems exist for response 
assessment to neoadjuvant chemotherapy, the general consensus is 
to consider greater than 90% necrosis and less than 90% necrosis 
as good and poor responders respectively. 
In our study lesser number of patients (38%) achieved 
greater than 90% necrosis, and a majority (62%) were poor 
responders. Similar to our study the European Osteosarcoma 
Intergroup (EOI) have analyzed a total of 570 patients and reported 
28% as good responders and 72% as poor responders27. Many of 
the patients included in this analysis did not receive high dose 
methotrexate which explains the reason for lesser number of 
patients showing good histologic response. Similarly in our study 
none of the patients received high dose methotrexate . 
In contrast two other studies that used high dose 
methotrexate has shown greater response to induction 
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chemotherapy. The Rizzoli institute has analyzed more than 1000 
patients over a 19 year period from 1983 to 2002 and reported 59% 
good responders and 41%  as poor responders28. The COSS 
database which analyzed 1700 patients between 1980 and 1998, 
reported 55.6% having good response to therapy and 44.4% having 
poor response9. All three studies together suggest that good 
responders are expected to have a 5-year survival of approximately 
75% and poor responders in the range of 45% to 55%, depending 
on the treatment. In our study good responders had 88% 5-year 
overall survival and poor responders 59%. 
Response to chemotherapy has been shown to affect 
prognosis in many studies9,29,30, but there are studies which report 
that this factor doesn’t influence prognosis26. In our study response 
to chemotherapy was found to be a significant factor affecting 
prognosis and local recurrence. 
Tumor size is another factor found to affect prognosis of 
patients with osteosarcoma unfavourably9. In our study tumors 
based on size more or less than 8cms did not affect prognosis. 
Similarly Rizzoli institute study which quantitatively evaluated 
tumor size, found that this factor did not affect prognosis26. Age at 
presentation particularly above forty years has shown poor 
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prognosis9. In our study we evaluated patients presenting less than 
or more than 20 years of age and found that this factor did not 
affect prognosis. 
The number of chemotherapy cycles varied depending on the 
time taken for customizing the prosthesis. Hence this factor was 
analyzed if it affected the survival. Patients were analyzed 
depending on whether they have received three or more cycles of 
chemotherapy and was found not to affect the survival. 
Intensification of preoperative therapy to increase the number of 
favourable responders was studied at MSKCC, T12 protocol29. In 
this study when preoperative therapy was lengthened, histologic 
response loses its prognostic value and did not change the long 
term outcome of these patients. 
Thirteen patients had suspicious nodules in lung at 
presentation. Two patients underwent thoracotomy and excision of 
the nodules, one was found to be metastatic and the other fibrotic 
lesion. All these patients had local tumor suitable for salvage and 
hence underwent limb salvage surgery. Following induction 
chemotherapy, re-assessment prior to surgery revealed 
disappearance of the nodules in five patients. Five of the thirteen 
patients developed lung metastases at follow up. The most 
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consistent prognostic factor at diagnosis is the presence of 
clinically detectable metastatic disease, which confers an 
unfavourable prognosis9,31. 
In our study  local recurrence is found to be higher when 
compared to international studies. Of the various factors analysed 
only histological response to preoperative chemotherapy was found 
to be a significant risk factor. Though not statistically significant, 
open biopsy could still be considered a risk factor for local 
recurrence. In a study from Italy, the following factors were found 
to be directly related to the development of local recurrence: a) the 
quality of the surgical margins, b) site of the biopsy as well as 
complications related to the biopsy procedure, c) local response to 
preoperative chemotherapy32. 
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The reported incidence of local recurrences in the literature 
are as follows. 
Journal  Author Number 
of patients 
Local 
recurrence 
% 
Acta Orthop Scand 
1998;69(3):230  
Bacci et al33  453 6 
J Bone Joint Surg Am 
1994;76(5):649  
Rougraff BT et 
al25  
73 11 
Ann Oncol 
1997;8:899-903  
Picci P et al32  365 6 
Cancer Control 
2005;12(1):57  
Ebeid W16 31(with 
pathologic
al 
fracture) 
6 
Present  study  92 13 
 
Bacci et al33 retrospectively evaluated 540 patients in three 
multicenter studies over a ten year period. The local recurrence rate 
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was 8% in poor responders and 3% in good responders. 84% of the 
540 patients underwent limb-salvage surgery and had a local 
recurrence rate of 6%. Local recurrence did not correlate with 
patient age, gender, histologic type, site and volume, pathologic 
fracture incidence, chemotherapy or type of surgical procedure. In 
our study the rate of local recurrence was 16% in poor responders 
and 3% in good responders. 
In general amputation is considered in patients having 
extensive disease where a functional limb could not be 
reconstructed. The local extent of tumor on disease free survival 
was studied by Spanier ST al at the University of Florida42. The 
tumors were classified on the basis of local extension as : E1- the 
tumor touches but not elevate or penetrate the periosteum; E2- the 
tumor elevates but does not penetrate the periosteum; E3- the 
tumor penetrates into, but not through the periosteum; E4- there is 
minimum extraperiosteal extension without invasion of another 
structure,such as muscle, tendon or ligament; E5- the tumor 
invades one additional structure (a muscle, ligament or tendon) and 
E6- the tumor invades two or more structures adjacent to the bone. 
The cumulative probabilities of disease-free survival at five years 
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were 79.8 + 9.3% for Enneking stage IIB without E6 tumor and 
17.6  + 11.3% for those who had stage IIB E6 tumor.  
In patients where limb salvage is feasible, there could be still 
be patients who portend a poor prognosis and have increased risk 
of local recurrence depending on the soft tissue involvement. We 
tried to subclassify these patients as having extensive soft tissue 
disease based on specific criterias. These patients are found to have 
increased local recurrence., distant metastasis and decreased 
survival, though the results are not significant. The 
subclassification of soft tissue extension is similar to the Spanier 
ST et al classification of local extension of tumor. The extensive 
soft tissue disease corresponds to E6 subcategory and both these 
studies have shown decreased disease free survival in this group.  
Many centres consider tumor size and volume as prognostic 
factors24,43.  
Considering these facts the tumors that are of large volume 
and have extensive soft tissue extension are likely to have poorer 
survival. But the observation from different institutes have shown 
different results. Long term outcomes from the German group, 
Rougraff BT et al 23 have shown no difference in the disease free or 
overall survival between the groups undergoing limb salvage 
55 
 
surgery or amputation or disarticulation. The study from Italian 
Rizzoli institute, Bacci et al 24 has shown improved survival for 
limb salvage group and patients with low tumor volume. 
 
 
Subgroups Disease free 
survival  
Overall 
survival 
P value 
Rougraff 
BT 23 
 
Limb salvage surgery 41% 46%  
Above knee amputation 41% 50%  
Hip disarticulation 46% 46% P=0.84 
Bacci 24 Limb salvage surgery 61%   
Amputation 46%  P NS 
Volume < 150 ml 65%   
Volume > 150 ml 52%  P NS 
Spanier 42 Stage IIB, No E6 79.8% 82.3%  
Stage IIB, with E6 17.6% 37.8%  
Our study Minimal soft tissue 
extension 
61.7% 72.3%  
Extensive soft tissue 
extension 
30.7% 49.3% P=0.33
 
Extensive soft tissue involvement have risk of developing 
distant metastasis similar to patients undergoing amputation in 
view of large volume disease. Hence if technically feasible these 
patients can be considered for limb salvage surgery.  
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The two most common prosthesis related complications we 
encountered was prosthesis infection and fracture. Prosthesis 
infection rate is 11.9% (n=11). These were treated by prosthesis 
removal in five and amputation in six. Prosthesis fracture rate is 
18.4% (n=17), managed by redo prosthesis in eleven, prosthesis 
removal in three, and two refused treatment. Both infection and 
fracture occurred commonly in distal femoral prosthesis (8 
infections and 14 fractures).   
Prosthesis infection reported in the literature ranges between 
0 to 35%35,37. In the Indian series reported by M V Natarajan et al, 
periprosthetic fracture and infection were the most common 
complications36. Prosthesis fracture is high in our patients, the 
reason may be due to use of stainless steel prosthesis. Since 2003, 
titanium prosthesis are being used and fracture rate has come 
down. 
Prosthesis failure is defined as removal of the implant for 
any reason. The durability of endoprosthesis is influenced by many 
factors, but the anticipated event-free five-year survival for 
proximal femur reconstructions is 90%, about 50% for distal femur 
and just over 50% for proximal tibia38. In our study the overall 
prosthesis survival rate is 57%, for distal femur it is 66% and 
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proximal tibia 70%. Henshaw et al in 1998, reported on long-term 
prosthetic survival analysis of 100 patients treated with modular 
prosthesis38. The survival rate for all sites was 88%, for distal 
femur and proximal tibia, 90% and 78% respectively. The 
decreased prosthesis survival in our study is due to increased 
infection rates, prosthesis fractures and local recurrence.  
The over-all rates of revision, infection, amputation and 
local recurrence are 33% (thirty patients), 12% (eleven patients), 
21% (nineteen patients) and 13% (twelve patients) respectively. 
Malawer M et al similarly has reported on prosthesis survival and 
clinical results with use of large segment prosthesis in 82 patients 
and the reported over-all rates of revision, infection, amputation 
and local recurrence were 15%, 13%, 11% and 6% respectively39. 
Functional assessment is done following limb salvage 
surgery using either Musculoskeletal tumor society scoring system 
(MSTS) or the Toronto extremity salvage score (TESS). In the 
modified MSTS score proposed by Enneking et al19 six factors- 
pain, function, emotional acceptance, supports, walking ability and 
gait are analyzed. In our study the average score was 25 out of 30, 
revealing a good functional outcome. In the literature functional 
assessment following limb salvage surgery has been compared 
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with amputation. In  studies by Johansen R et al41, Rougraff BT et 
al25 limb salvage surgery is associated with better functional 
outcome than that observed with amputation.  
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CONCLUSION 
 
1. Treatment  of  osteosarcoma has seen a paradigm shift in the 
management and today limb salvage surgery is possible in a 
majority of patients. Survival outcomes are excellent in our 
study and in par with international standards. 
2. Needle biopsy is the preferred method of obtaining diagnosis, 
preferably to be done by the centre planning the definitive 
treatment. 
3.  Tumor response to neoadjuvant chemotherapy is the most 
important and valid prognostic factor predicting survival. 
4.  Extensive soft tissue involvement and tumor necrosis following 
neoadjuvant chemotherapy were found to be risk factors, for the 
increased local recurrence, that has been observed in this study. 
In patients with extensive soft tissue extension, limb salvage 
surgery can be considered if technically feasible, although they 
have decreased survival similar to patients undergoing 
amputations. Our study has got its limitations as the results of 
the analysis of this group of patients are not statistically 
significant and due to lesser number of patients. The influence 
of this subgroup of patients undergoing limb salvage surgery, 
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on local recurrence and survival needs to be validated in a 
prospective study involving more number of patients.  
5. Functional outcome after limb salvage surgery is excellent in 
our patients. 
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